Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

The FLASH Study: A Study of Roflumilast Versus Placebo in Patients With Asthma (BY217/M2-023)

ClinicalTrials.gov ID: NCT00076076

Public ClinicalTrials.gov record NCT00076076. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 26, 2026, 10:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

The FLASH Study: A Randomized, Controlled Study of Roflumilast 250 mcg and 500 mcg Versus Placebo in Patients With Asthma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to confirm the dose of roflumilast to be used for asthma management by comparing the effects of 250 mcg and 500 mcg oral roflumilast with placebo on pulmonary function and asthma symptoms.

Study identification

NCT ID
NCT00076076
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
822 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2003
Primary completion
Not listed
Completion
May 31, 2005
Last update posted
Dec 1, 2016

2003 – 2005

United States locations

U.S. sites
39
U.S. states
39
U.S. cities
39
Facility City State ZIP Site status
ALTANA Pharma Cities in Alabama Alabama — —
ALTANA Pharma Cities in Arizona Arizona — —
ALTANA Pharma Cities in Arkansas Arkansas — —
ALTANA Pharma Cities in California California — —
ALTANA Pharma Cities in Colorado Colorado — —
ALTANA Pharma Cities in Connecticut Connecticut — —
ALTANA Pharma Cities in Delaware Delaware — —
ALTANA Pharma Cities in Florida Florida — —
ALTANA Pharma Cities in Georgia Georgia — —
ALTANA Pharma Cities in Illinois Illinois — —
ALTANA Pharma Cities in Indiana Indiana — —
ALTANA Pharma Cities in Kansas Kansas — —
ALTANA Pharma Cities in Kentucky Kentucky — —
ALTANA Pharma Cities in Louisiana Louisiana — —
ALTANA Pharma Cities in Maine Maine — —
ALTANA Pharma Cities in Maryland Maryland — —
ALTANA Pharma Cities in Massachusetts Massachusetts — —
ALTANA Pharma Cities in Michigan Michigan — —
ALTANA Pharma Cities in Minnesota Minnesota — —
ALTANA Pharma Cities in Missouri Missouri — —
ALTANA Pharma Cities in Montana Montana — —
ALTANA Pharma Cities in Nebraska Nebraska — —
ALTANA Pharma Cities in Nevada Nevada — —
ALTANA Pharma Cities in New Jersey New Jersey — —
ALTANA Pharma Cities in New York New York — —
ALTANA Pharma Cities in North Carolina North Carolina — —
ALTANA Pharma Cities in Ohio Ohio — —
ALTANA Pharma Cities in Oklahoma Oklahoma — —
ALTANA Pharma Cities in Oregon Oregon — —
ALTANA Pharma Cities in Pennsylvania Pennsylvania — —
ALTANA Pharma Cities in Rhode Island Rhode Island — —
ALTANA Pharma Cities in South Carolina South Carolina — —
ALTANA Pharma Cities in Tennessee Tennessee — —
ALTANA Pharma Cities in Texas Texas — —
ALTANA Pharma Cities in Utah Utah — —
ALTANA Pharma Cities in Vermont Vermont — —
ALTANA Pharma Cities in Virginia Virginia — —
ALTANA Pharma Cities in Washington Washington — —
ALTANA Pharma Cities in West Virginia West Virginia — —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00076076, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 1, 2016 · Synced Sep 26, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00076076 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →